Literature DB >> 20924794

ASCI 2010 standardized practice protocol for cardiac magnetic resonance imaging: a report of the Asian society of cardiovascular imaging cardiac computed tomography and cardiac magnetic resonance imaging guideline working group.

Carmen W S Chan, Byoung Wook Choi, Masahiro Jinzaki, Kakuya Kitagawa, I-Chen Tsai, Hwan Seok Yong, Wei Yu.   

Abstract

These practice guidelines are recommended by the Asian Society of Cardiovascular Imaging (ASCI), the sole society in Asia designated for cardiovascular imaging, to provide a framework to healthcare providers for suggested essential elements in cardiac magnetic resonance (CMR) examinations of different disease spectra. The guideline is composed of recommendations on the general technique, acquisition of some basic modules, and protocols on stress tests. The protocols for specific diseases are provided in a table format for quick reference to be easily utilized for everyday clinical CMR.

Entities:  

Mesh:

Year:  2010        PMID: 20924794      PMCID: PMC2996543          DOI: 10.1007/s10554-010-9708-y

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


Introduction

As the healthcare system, resource allocation, and pattern of diseases [1, 2] in Asia are different from those in Western Society, this practice protocol is recommended by the Asian Society of Cardiovascular Imaging (ASCI), the sole society dedicated to cardiovascular imaging in Asia, to provide a frame work for the suggested essential elements in cardiac magnetic resonance (CMR) examinations. It must be emphasized that this guideline has been built on previously published guidelines from various professional societies [3-6], but is customized for CMR practice in Asia with its unique characteristics and where thalassemia [7-9] and valvular heart disease are common. The ultimate decision regarding the propriety of any specific procedure must be made after mutual communication with the referring physicians; the understanding of individual patient’s condition; and the availability of resources, knowledge and technology provided by their respective centers by the responsible individuals participating and performing the CMR procedures. The practice protocol starts with recommendations on the general technique and is followed by techniques on the acquisition of some basic modules. Recommended practice protocols on stress tests with separate checklists and monitoring sheets are provided. Protocols for specific diseases are summarized in a table format for quick reference.

Guidelines

Recommended practice protocol for CMR examination

Patient preparation

Check for any contraindication for MR examination, stress study, and contrast administration, if needed. Obtain informed consent for the MR examination. Advise patient on fasting before examination. This is not mandatory, but is advised. Have patient stop intake of caffeine-containing food and beverages, theophylline or dipyridamole at least 24 h before adenosine study; avoid beta-blocker and nitrates for dobutamine study. Educate and provide practice to patients on the breathing instruction. Provide the patient with ear plugs. Prepare the skin of the chest and/or abdomen for optimal attachment of electrodes for cardiac and respiratory gating. Position the patient in the best comfortable supine position. Have the patient place the arms above the head to decrease wrap artifact. It is acceptable to put the arms along the side or crossed over the chest if the patient cannot tolerate arms overhead for extended periods of time.

Equipment and safety

Monitoring equipment (blood pressure, electrocardiogram, intercom communication with patients) Resuscitation facilities : emergency resuscitation policy in place availability of resuscitation team with medical/nursing staff having ACLS accreditation logistics for transferring patient to designated resuscitation area outside scanner resuscitation trolley with full set of emergency medications and equipment external pacer and defibrillator oxygen supply beta-blockers, nitrates, and aminophylline at hand Stress MRI testing. Detail on safety and equipment needed is listed in the performance protocol for the adenosine and dobutamine studies

Recommended practice protocol on basic modules

See Fig. 1 for a quick reference on the acquisition of major imaging planes described below.
Fig. 1

A road map for major imaging planes of the cardiac magnetic resonance study

A road map for major imaging planes of the cardiac magnetic resonance study

Left ventricular (LV) structure and function module

All scans are recommended to be performed as breathhold, multiphase steady state free precession (SSFP) imaging at the end of the expiratory phase using all elements on the cardiac coil. All 17 segments of the heart can be covered by a combination of three short axis and two long axis views (four chambers and two chambers). Scout imaging—multistack three plane localizers: transtransaxial, coronal, sagittal Calibrate for parallel imaging technique, if it is to be used. Shimming Transaxial (8–10 mm) set of SSFP or fast spin echo (FSE) images through the chest. Vertical long axis scout cine images The vertical long axis scout cine plane is prescribed from the axial localizer at the level of mitral and tricuspid valves. The slice through the LV apex and centre of the mitral valve is prescribed. Horizontal long axis scout cine images. The horizontal long axis scout cine plane is prescribed from the end systolic phase of the vertical long axis scout cine image. Position the slice at the center of the mitral valve and angulate through the LV apex. Scroll through the diastolic images to ensure the left atrium is included and properly imaged. Short axis cine images. The short axis cine planes are prescribed from previously acquired long axis scout cines at diastole, starting from the mitral valve plane through the LV apex, covering the whole ventricle perpendicular to the interventricular septum on horizontal long axis scout cine images. Slice thickness 6–8 mm; no gap Temporal resolution ≤45 ms between phases Parallel imaging to shorten scanning time Other long axis cine images The four chamber cine plane is prescribed from the vertical long axis scout cine and short axis cine images. The cut plane should pass through the LV apex and centre of mitral valve on the vertical long axis scout cine image. On the short axis cine image, angulate the cut plane so that it passes through the center of the LV chamber and lower corner of the RV border sure to avoid bisecting the LV outflow tract in the basal short axis view. The two chamber cine image is prescribed by a cut plane that bisects the LV apex and centre of the mitral valve in the four chamber view, as well as passing through the mid LV chamber in the short axis view. The cut plane needs to be in parallel to the ventricular septum in both views. The three chamber cine image is prescribed by a cut plane parallel to the long axis with the bisecting mitral valve and apex as well as the bisecting LV outflow tract in basal short axis view. The LV outflow tract (LVOT) long axis is obtained in the oblique coronal plane from the true axial scout images by positioning the slice through the aortic root and directing it toward the LV apex. Additional views of cine images. A contiguous stack of transaxial steady state free precession cine images from the top of the aortic arch to the inferior wall of the LV is recommended for congenital heart disease.

Right ventricular (RV) structure and function module

RV short axis views are acquired in a similar fashion to the LV structure and function module. Use a transaxial stack of cines covering the RV for best identification of the tricuspid valve plane. Right ventricular two chamber long axis view Obtain the right ventricular two chamber long axis images from four chamber images Position the centre of the slice in the middle of the tricuspid valve and angulate through the RV apex. Scroll through phases to ensure the slice passes through the end-systolic and end-diastolic RV apex of the four chamber images. Right ventricular outflow view (RVOT). Prescribe by placing the slice through the centre of main pulmonary artery and the RV apex through a set of axial images. Right ventricular inflow and outflow view. An inflow/outflow plane of the RV can be acquired using a three-point plane. Place the first point on the tricuspid valve of the four chamber view. Place the second point on the RV apex of the two chamber RV view. Place the third point on the pulmonary valve of the RVOT view.

Gadolinium first pass perfusion module

Use scout imaging as per the LV structure and function module. Use saturation-recovery imaging with gradient echo-echo planar imaging (GRE-EPI) hybrid, GRE, or SSFP readout. Use at least three short axis slices per each heart beat (basal, mid, and apical level of LV). Add one slice in four chamber (for sepal/lateral segment ischemia) or two chamber view (for anterior/inferior segment) if the length of the RR interval permits. Acquire the apical short axis slice first and the most basal short axis last during the cardiac cycle to minimize cardiac motion artifacts. Use a slice thickness of 8–10 mm, in-plane resolution, ~<3 mm; twofold acceleration and temporal resolution <100 ms or shorter. Do a dry run at the end expiration for 5–10 phases to check and correct any position and phase wrap artifacts. Use the following parameters: Give contrast (0.05–0.1 mmol/kg, 3–7 ml/s) followed by at least 30 ml saline flush (5–7 ml/s) Start breathhold during early phases of contrast infusion before contrast reaches the LV cavity. Readout for 50–60 heart beats to capture the contrast wash-in and wash-out through LV myocardium.

Late gadolinium enhancement (LGE) module

Wait for 10 min after administration of cumulative dose of 0.1–0.2 mmol/kg gadolinium. A shorter delay time may be considered if lower doses of contrast are used. Use 2D segmented inversion recovery GRE imaging during the end of the diastolic phase. Prescribe the slices at the identical location, views, and thicknesses as for cine imaging (short- and long-axis views). In-plane resolution, ~1.4–1.8 mm; adjust acquisition duration to a shorter RR interval in tachycardia. Set inversion time to null normal myocardium. Adjust the read-out according to heart rate. Every other heart beat in normal setting of heart rate; every heart beat in the setting of bradycardia, and every third heart beat in the setting of tachycardia or arrhythmia.

T2-weighted imaging

Consider using either body coil or functional surface coil intensity correction algorithms. Use breathhold, pre-contrast segmented FSE imaging (double inversion recovery). Select slice locations based on the suspected area of acute edema or inflammation on cine images. Use a thick (10–12 mm) slice. Obtain short axis, mid ventricular slices by multiple breathholds, spoiled gradient echo sequences with nine echo time (5.6–18 ms) for T2* measurement for iron detection. Adjust the TR between the 9 RF (segment) pulses according to the different TE times.

Valvular flow and shunt assessment module

Quantitative flow measurement For the flow velocity and volume, the plane of measurement should be perpendicular to the vessel and distal to valve leaflet tips of interest. Adapt velocity encoding to actual velocity by the lowest velocity without aliasing, and use the lowest TE possible for high velocity jet flows. Specific plane for phase contrast (PC) flow acquisition. For the acquisition of different chamber views stated below, please refer to the basic modules on structure and function of LV and RV in Sections A & B. Mitral Valve: Plan on the end-systolic two chamber and four chamber cine images. The center of the slice is placed in the middle of the mitral valve and angulated parallel to the mitral valve. Tricuspid Valve: Plan on true four-chamber and RV two-chamber images at the end systolic phase. The center of the slice is placed in the middle of the tricuspid valve and angulated parallel to the tricuspid valve. Aortic Valve: Alignment of the imaging plan for the aortic valve is from the three chamber and LVOT views. The imaging plane should be positioned just above the aortic valve, yet just below the origin of the coronary arteries. The LVOT view is prescribed perpendicular to the three chamber view. Pulmonary Valve: Align the imaging plane from two orthogonal RVOT views and place the plane just above the pulmonary valve. The first RVOT view is prescribed from an oblique plane through the main PA and RV on a set of axial images. The second RVOT plane is prescribed perpendicular to the first RVOT. Pulmonary Arteries: Main pulmonary artery (MPA) Prescribe from sagittal localizer and obtain a few cine slices parallel to the MPA. The imaging plane for flow acquisition should be perpendicular to the direction of flow to the MPA on these images. The usual peak velocity is 180 cm/s. The encoding velocity recommended for the first measurement or for flow measurement is 180 cm/s. Left pulmonary artery (LPA) and right pulmonary artery (RPA) Imaging planes through the LPA and RPA should be perpendicular to the direction of flow and proximal to the first branching vessel. In general, these planes are usually 1–1.5 cm distal to the MPA bifurcation. The usual velocity for peak measurement is 60–120 cm/s. The recommended encoding velocity for the first measurement or for flow measurement is 200 cm/s. Ascending Aorta: Prescribe the imaging plane from the coronal localizer. The flow acquisition is performed perpendicular to the flow direction of the ascending aorta, about 1.5–2 cm above the aortic valve at the pulmonary bifurcation level. The usual peak velocity measurement is 100–160 cm/s. The recommended encoding velocity for the first measurement or for flow measurement is 200 cm/s. Qualitative assessment Use gradient echo or hybrid gradient echo/echo planar imaging as either is better in visualizing the severity of regurgitant jets or turbulence across shunts. For the morphology and planimetry of valve orifice, optimize the angle and level with SSFP in the plane of the valve of interest and use three contiguous 5 mm-thick high resolution cines transecting the line of the jet and moving from orifice level to immediately downstream. Specific plane for assessment: Mitral valve: horizontal and vertical long axis, LVOT view Aortic valve: LVOT and coronal view Tricuspid valve: horizontal long axis and transaxial view Pulmonary valve: RV long axis or RVOT view

Recommended protocol for adenosine stress test

Follow the checklist attached and set up according to the monitoring sheet for adenosine stress myocardial perfusion test. Perform LV structure and function module as listed or alternatively acquire these images at between stress and rest perfusion to shorten scanning time. Start continuous adenosine infusion (at least 3 min, preferably 4–6 min continuous infusion of 140 μg/kg body weight/min) and then Perform the gadolinium first pass perfusion module; update the heart rate in response to the heart rate increase caused by adenosine. Gadolinium is injected (0.05–0.1 mmol/kg) during the last minute of adenosine infusion. Stop adenosine infusion after imaging for 50–60 heart beats when the gadolinium has passed through LV myocardium. Continuous ECG monitoring, oxygen saturation monitoring and repeated BP measured at baseline, during infusion, and for at least 2 min post-infusion of adenosine (see the monitoring sheet). Rest Perfusion Perform only after at least 10 min washout period for the gadolinium from stress perfusion imaging. Repeat perfusion imaging without adenosine using same dose of gadolinium and at the same slice location, again update the heart rate. Consider skipping if the stress perfusion is free from artifact. However, additional gadolinium may be considered for late gadolinium enhancement imaging (for a cumulative total dose of 0.1–0.2 mmol/kg). Perform the LGE module after waiting for about 10 min after the last dose of contrast.

Recommended protocol for dobutamine stress test

Low dose dobutamine infusion at 10 μg/kg for 5–10 min is an alternative to look for contractile reserve only. Follow the attached checklist and set up according to the monitoring sheet for dobutamine stress myocardial perfusion test. Follow baseline LV structure and function module. Dobutamine continuous infusion: Increase the dobutamine infusion in increments of 10 μg/kg body weight/minute every 3 min starting at 10 μg/kg body weight/min until target heart rate [85% × (220-age)] is reached. Add atropine 0.3 mg in fractional doses up to 2 mg, if heart rate response is poor. Repeat 3 short axis (basal, mid ventricular, and distal views) and 3 long axis cine views during each increment of dobutamine dosing. Continuously monitor ECG and oxygen, and measure BP at baseline, during each stage and at least 10 min after stress test (see the monitoring sheet). View cine loops online as they are being acquired at each stage during real-time or almost at real-time. Optimize the temporal resolution at every dosage as the heart rate increases. Stop test at detection of any new wall motion or thickening abnormality; systolic blood pressure increase >240 mmHg and/or diastolic blood pressure >120 mmHg; Blood pressure decrease >20 mmHg below baseline systolic blood pressure and/or decrease >40 mmHg from a previous level; severe chest pain or other intractable symptoms; complex cardiac arrhythmias or achievement of peak heart rate. Perform first pass perfusion at peak stress with gadolinium at 0.05–0.075 mmol/kg as described in the perfusion module, wait for 20 min before acquisition of rest perfusion. Perform the LGE module after waiting for at least 10 min after the last dose of gadolinium injection (at a cumulative dose of 0.1–0.2 mmol/kg).

Conclusion

The elements of the above practice guidelines recommended by ASCI are based on the currently available acquisition technology and knowledge on specific diseases. ASCI will continue to observe the field and provide the most up-to-date information to assist in the delivery of the best patient care (Table 1).
Table 1

A quick reference on the recommended study protocol in specific diseases (optional items are highlighted in blue)

A quick reference on the recommended study protocol in specific diseases (optional items are highlighted in blue)
Table 2

Checklist for adenosine stress myocardial test

Pre-procedureChecked
 I. Check for contraindication for adenosine stress test
  1. Known hypersensitivity to adenosine
  2. Known or suspected bronchoconstrictive or bronchospastic disease
  3. Heart block more than first degree
  4. Significant sinus bradycardia (resting heart rate <45 bpm)
  5. Systemic arterial hypotension (<90 mmHg) or severe arterial hypertension
  6. Recent myocardial infarction within 3 days
 II. Obtain informed consent
 III. Perform pre-procedure 12 leads ECG and review by doctor in charge
 IV. Place two angiocatheters intravenously to each arm:
  1. One IV 20G in antecubital fossa for contrast
  2. One IV 20–22G for adenosine infusion
 V. Set up infusion pump for adenosine:
  Drugs dosage: adenosine 0.14mg/kg/min
  Patient’s body weight (BW) = _________ kg; Adenosine concentration _________mg/ml
  0.140 (mg/kg/min) × BW (kg)/Adenosine concentration (mg/ml) = 
  Infusion rate _________ (ml/min) =_________ (ml/h)
  Total dose of adenosine to be administrated:
  0.14 (mg/kg/min) × BW (kg) × Infusion time (min) = _________ mg
During-procedure
 1. Oxygen 2 l/min per nasal cannula
 2. Set BP cuff to manual mode. Place BP cuff opposite arm as med administration.
 3. Record baseline vital signs- prior to medication administration
 4. Aminophylline 125 mg in 50 ml normal saline IVB over 5–6 min prn chest pain and shortness of breath
 5. Start adenosine infusion at am/pm (time). Continue vital sign monitoring as shown
Post procedure
 1. Perform post stress ECG and review
 2. Record final vital signs prior to discharge. Report any patient complaints to doctor in charge
Table 3

Patient monitoring during adenosine stress cardiac MR examination

Table 4

Checklist for dobutamine stress myocardial test

Pre-procedureChecked
 I. Check for contraindication for dobutamine stress test
  1. Severe systemic arterial hypertension (≥220/120 mmHg)
  2. Unstable angina
  3. High grade aortic stenosis (aortic valve area <1 cm/peak aortic valve gradient >50 mmHg)
  4. Uncontrolled or complex cardiac arrhythmias
  5. Haemodynamically significant hypertrophic obstructive cardiomyopathy
  6. Uncontrolled heart failure
  7. Myocarditis, endocarditis and pericarditis
  8. History of sudden death
  9. Aortic dissection/high grade aortic aneurysm
  10. Mobile left ventricular or left atrial thrombus
 II. Check list for contraindications for atropine
  1. Advance heart block
  2. Glaucoma
  3. Pyloric stenosis
  4. Obstructive uropathy
  5. Myasthenia gravis
 II. Obtain informed consent
 III. Perform pre-procedure 12 leads ECG and review by doctor in charge
 IV. Place two angiocatheters intravenously to each arm:
  1. One IV 20G in antecubital fossa for contrast
  2. One IV 20–22G for adenosine infusion
 V. Set up infusion pump for dobutamine infusion:
 VI. Additional medication to be ready for use in examination room
  1. TNG table
  2. Metropolol 5 mg/ml
  3. Atropine 0.6 ml × 3 ampules
  4. NS flush
 During-procedure
  1. Oxygen 2 l per nasal cannula
  2. Set BP cuff to manual mode. Place BP cuff opposite arm as med administration.
  3. Record baseline vital signs- prior to medication administration
  4. Record time at the start of dobutmaine infusion. Continue vital sign monitoring whenever change of dosage and prn
 Post procedure
  1. Perform post stress ECG and review
  2. Record total amount of drugs given
  3. Record final vital signs prior to discharge. Report any patient complaints to doctor in charge
Table 5

Patient monitoring during dobutamine stress cardiac MR examination

Table 6

Adenosine infusion protocol (0.14 mg/kg/min over 6 min) adenosine concentration: 3 mg/ml

Wt (kg)Wt (lbs)Adenosine (mg/min)Adenosine (ml/h)Adenosine total doseWt (kg)Wt (lbs)Adenosine (mg/min)Adenosine (ml/h)Adenosine total dose
40885.6112347516510.521063
41905.7114347616710.621364
42925.9118357716910.821665
43956.0120367817210.921866
44976.1122377917411.122166
45996.3126388017611.222467
461016.4129398117811.322768
471036.6132398218011.523069
481066.7134408318311.623270
491086.9137418418511.823571
501107.0140428518711.923871
511127.1143438618912.024172
521147.3146448719112.224473
531177.4148458819412.324674
541197.6151458919612.524975
551217.7154469019812.625276
561237.8157479120012.725576
571258.0160489220212.925877
581288.1162499320513.026078
591308.3165509420713.226379
601328.4168509520913.326680
611348.5171519621113.426981
621368.7174529721313.627281
631398.8176539821613.727482
641419.0179549921813.927783
651439.11825510022014.028084
661459.21855510122214.128385
671479.41885610222414.328686
681509.51905710322714.428887
691529.71935810422914.629187
701549.81965910523114.729488
7115619.91996010623314.829789
7215810.12026010723515.030090
7316110.22046110823815.130291
7416310.42076210924015.330592
Table 7

Adenosine infusion protocol (0.14 mg/kg/min over 6 min) adenosine concentration: 2 mg/ml

Wt (kg)Wt (lbs)Adenosine (mg/min)Adenosine (ml/h)Adenosine total doseWt (kg)Wt (lbs)Adenosine (mg/min)Adenosine (ml/h)Adenosine total dose
40885.6168347516510.531563
41905.7171347616710.631864
42925.9177357716910.832465
43956.0180367817210.932766
44976.1183377917411.133366
45996.3189388017611.233667
461016.4192398117811.333968
471036.6198398218011.534569
481066.7201408318311.634870
491086.9207418418511.835471
501107.0210428518711.935771
511127.1213438618912.036072
521147.3219448719112.236673
531177.4222458819412.336974
541197.6228458919612.537575
551217.7231469019812.637876
561237.8234479120012.738176
571258.0240489220212.938777
581288.1243499320513.039078
591308.3249509420713.239679
601328.4252509520913.339980
611348.5255519621113.440281
621368.7261529721313.640881
631398.8264539821613.741182
641419.0270549921813.941783
651439.12735510022014.042084
661459.22765510122214.142385
671479.42825610222414.342986
681509.52855710322714.443287
691529.72915810422914.643887
701549.82945910523114.744188
7115619.95976010623314.844489
7215810.13036010723515.045090
7316110.23066110823815.145391
7416310.43126210924015.345992
  10 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

Review 2.  ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology.

Authors:  Robert C Hendel; Manesh R Patel; Christopher M Kramer; Michael Poon; Robert C Hendel; James C Carr; Nancy A Gerstad; Linda D Gillam; John McB Hodgson; Raymond J Kim; Christopher M Kramer; John R Lesser; Edward T Martin; Joseph V Messer; Rita F Redberg; Geoffrey D Rubin; John S Rumsfeld; Allen J Taylor; Wm Guy Weigold; Pamela K Woodard; Ralph G Brindis; Robert C Hendel; Pamela S Douglas; Eric D Peterson; Michael J Wolk; Joseph M Allen; Manesh R Patel
Journal:  J Am Coll Cardiol       Date:  2006-10-03       Impact factor: 24.094

3.  ACC/AHA/ACR/ASE/ASNC/HRS/NASCI/RSNA/SAIP/SCAI/ SCCT/SCMR/SIR 2008 Key Data Elements and Definitions for Cardiac Imaging: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Cardiac Imaging).

Authors:  Robert C Hendel; Matthew J Budoff; John F Cardella; Charles E Chambers; John M Dent; David M Fitzgerald; John McB Hodgson; Elizabeth Klodas; Christopher M Kramer; Arthur E Stillman; Peter L Tilkemeier; R Parker Ward; Wm Guy Weigold; Richard D White; Pamela K Woodard
Journal:  Circulation       Date:  2008-12-08       Impact factor: 29.690

4.  Alpha-thalassaemia in Chinese: cord blood studies.

Authors:  D Todd; M C Lai; C A Braga; H N Soo
Journal:  Br J Haematol       Date:  1969-06       Impact factor: 6.998

5.  The screening of Chinese cord blood for haemoglobinopathies.

Authors:  A M Li; F T Lee; D Todd
Journal:  Hum Hered       Date:  1982       Impact factor: 0.444

6.  Global epidemiology of haemoglobin disorders and derived service indicators.

Authors:  Bernadette Modell; Matthew Darlison
Journal:  Bull World Health Organ       Date:  2008-06       Impact factor: 9.408

7.  Evaluation of a prenatal screening procedure for beta-thalassaemia carriers in a Chinese population based on the mean corpuscular volume (MCV).

Authors:  A Ghosh; J S Woo; C W Wan; C Machenry; V Wong; H K Ma; V Chan; T K Chan
Journal:  Prenat Diagn       Date:  1985 Jan-Feb       Impact factor: 3.050

8.  Cardiovascular magnetic resonance in myocarditis: A JACC White Paper.

Authors:  Matthias G Friedrich; Udo Sechtem; Jeanette Schulz-Menger; Godtfred Holmvang; Pauline Alakija; Leslie T Cooper; James A White; Hassan Abdel-Aty; Matthias Gutberlet; Sanjay Prasad; Anthony Aletras; Jean-Pierre Laissy; Ian Paterson; Neil G Filipchuk; Andreas Kumar; Matthias Pauschinger; Peter Liu
Journal:  J Am Coll Cardiol       Date:  2009-04-28       Impact factor: 24.094

9.  Appearance of microvascular obstruction on high resolution first-pass perfusion, early and late gadolinium enhancement CMR in patients with acute myocardial infarction.

Authors:  Adam N Mather; Timothy Lockie; Eike Nagel; Michael Marber; Divaka Perera; Simon Redwood; Aleksandra Radjenovic; Ansuman Saha; John P Greenwood; Sven Plein
Journal:  J Cardiovasc Magn Reson       Date:  2009-08-21       Impact factor: 5.364

Review 10.  Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols.

Authors:  Christopher M Kramer; Jorg Barkhausen; Scott D Flamm; Raymond J Kim; Eike Nagel
Journal:  J Cardiovasc Magn Reson       Date:  2008-07-07       Impact factor: 5.364

  10 in total
  6 in total

1.  Progress of the Asian Society of Cardiovascular Imaging.

Authors:  Yeon Hyeon Choe
Journal:  Int J Cardiovasc Imaging       Date:  2011-11-08       Impact factor: 2.357

2.  Evaluation of elevated left ventricular end diastolic pressure in patients with preserved ejection fraction using cardiac magnetic resonance.

Authors:  Chengjie Gao; Yijing Tao; Jingwei Pan; Chengxing Shen; Jiayin Zhang; Zhili Xia; Qing Wan; Hao Wu; Yajie Gao; Hong Shen; Zhigang Lu; Meng Wei
Journal:  Eur Radiol       Date:  2019-01-10       Impact factor: 5.315

3.  Cardiac MRI assessment of right ventricular function: impact of right bundle branch block on the evaluation of cardiac performance parameters.

Authors:  Robert Marterer; Zeng Hongchun; Sebastian Tschauner; Martin Koestenberger; Erich Sorantin
Journal:  Eur Radiol       Date:  2015-07-02       Impact factor: 5.315

4.  Guideline for Cardiovascular Magnetic Resonance Imaging from the Korean Society of Cardiovascular Imaging-Part 1: Standardized Protocol.

Authors:  Yeseul Jo; JeongJae Kim; Chul Hwan Park; Jae Wook Lee; Jee Hye Hur; Dong Hyun Yang; Bae Young Lee; Dong Jin Im; Su Jin Hong; Eun Young Kim; Eun Ah Park; Pan Ki Kim; Hwan Seok Yong
Journal:  Korean J Radiol       Date:  2019-09       Impact factor: 3.500

5.  History of the Asian Society of Cardiovascular Imaging.

Authors:  Wen Jeng Lee; Shyh Jye Chen; Yung Liang Wan
Journal:  Korean J Radiol       Date:  2021-02-24       Impact factor: 3.500

6.  The recent advances, drawbacks, and the future directions of CMRI in the diagnosis of IHD.

Authors:  Moram A Fagiry; Ikhlas Abdelaziz; Rob Davidson; Mustafa Z Mahmoud
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.